Literature DB >> 20506203

Should the Food and Drug Administration warning of malignancy in children receiving tumor necrosis factor alpha blockers change the way we treat children with juvenile idiopathic arthritis?

Thomas J A Lehman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20506203     DOI： 10.1002/art.27506

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  7 in total

1.  Pediatric rheumatology: JIA, treatment and possible risk of malignancies.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2010-12-07       Impact factor: 20.543

Review 2.  The development and assessment of biological treatments for children.

Authors:  Eve M D Smith; Helen E Foster; Michael W Beresford
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

Review 3.  Juvenile idiopathic arthritis: new insights into classification, measures of outcome, and pharmacotherapy.

Authors:  Michael W Beresford
Journal:  Paediatr Drugs       Date:  2011-06-01       Impact factor: 3.022

4.  Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.

Authors:  Timothy Beukelman; Kevin Haynes; Jeffrey R Curtis; Fenglong Xie; Lang Chen; Christina J Bemrich-Stolz; Elizabeth Delzell; Kenneth G Saag; Daniel H Solomon; James D Lewis
Journal:  Arthritis Rheum       Date:  2012-02-10

Review 5.  What is the background incidence of malignancy in children with rheumatic disease?

Authors:  Melissa L Mannion; Timothy Beukelman
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

Review 6.  Juvenile Idiopathic Arthritis: Diagnosis and Treatment.

Authors:  Gabriella Giancane; Alessandro Consolaro; Stefano Lanni; Sergio Davì; Benedetta Schiappapietra; Angelo Ravelli
Journal:  Rheumatol Ther       Date:  2016-08-12

7.  Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis.

Authors:  Victor C Kok; Jorng-Tzong Horng; Jing-Long Huang; Kuo-Wei Yeh; Jia-Jing Gau; Cheng-Wei Chang; Lai-Zhen Zhuang
Journal:  BMC Cancer       Date:  2014-08-29       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.